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Abstract
There has been much hype in the research and development of continuous glucose
monitoring technologies, driven by the enormous and rapidly expanding glucose
monitoring market and the large and growing base of diabetes patients. Continuous
glucose monitoring has shown significant benefits over traditional intermittent blood
glucose testing in reducing the risks of developing long-term complications associated
with diabetes, by maintaining blood glucose concentrations to near-normoglycemic levels
and reducing glycemic variability. In this thesis, commercially available continuous
glucose monitoring systems as well as those still in development are evaluated. SWOT
analysis shows that continuous glucose monitoring has a promising future, but there
remain a number of challenges to be overcome, such as accuracy, sensor span, data
handling, cost and reimbursement issues. It is concluded that continuous glucose
monitoring will be the roadmap for future diabetes management. Ongoing technological
advances in continuous glucose monitoring systems will hopefully close the loop for a
fully automated artificial pancreas and develop a cure for Type I diabetes.
Thesis Supervisor: Michael J. Cima
Title: Sumitomo Electric Industries Professor of Engineering
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Chapter 1. Introduction
Diabetes mellitus is a medical condition in which the body suffers from a metabolic
disorder and chronic hyperglycemia resulting from insufficient insulin secretion by the
pancreas and/or defects in insulin produced'. Some characteristic symptoms associated
with diabetes include thirst, polyuria, blurred vision, weight loss, and lethargy.
There are mainly three types of diabetes mellitus recognized by the World Health
Organization'. Type I and Type II are chronic conditions2: the first is caused by the
autoimmune destruction of the pancreatic beta cells; the latter is characterized by insulin
resistance in target tissues, that results in a need for excessively high amount of insulin.
90%-95 % of the diabetics are Type II. The third type is the gestational diabetes, which
occurs during pregnancy in women who are genetically predisposed to such conditions, is
similar to Type II diabetes; the insulin resistance is caused by the hormones produced
during pregnancy. Normally, gestational diabetes can be resolved upon the delivery of the
baby. Other types of diabetes that account for 1 %-5 % of all diagnosed cases are caused
by specific genetic mutations, pancreatic disease, drugs, etc.
Diabetes was the seventh leading cause of death listed on U.S. death certificates in 20063,
and is the only major disease with a rising death rate. The World Health Organization
estimates that the number of Americans diabetics will reach 30 million in 2030. There is
an imperative need for the management of diabetes to prevent long-term complications
that diabetes can lead to. Some of these complications include permanent blindness,
gangrene, kidney failure, coma and even death. Many studies have shown that people
with diabetes are exposed to much higher risks of developing cardiovascular, peripheral
vascular and cerebrovascular diseases. According to the National Diabetes Statistics 2007,
diabetes is the leading cause for kidney failure and blindness; the risk of developing
stroke is 2 to 4 times greater for diabetics 3.
It has been scientifically proven that the debilitating and costly micro-vascular
complications of diabetes can be prevented or slowed down by strictly controlling the
blood glucose concentrations to near-normoglycemia levels (Fig 1.1). Modem diabetes
management requires accurate administration of insulin and frequent testing of blood
glucose levels for Type I diabetes patients, and a combination of oral medications and
insulin injections with dietetic support and exercises for Type II diabetics.
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Fizure 1.1: AACE recommends less than or equal to 6.5 HbAlc. Alc test gives an
overview of patients' averaze blood glucose control for the past few months4 -6.
To control blood glucose level is particularly crucial for patients relying on insulin
therapy. Diabetes patients are recommended to measure their blood glucose frequently.
However, only 37% of diabetes patients can achieve the level of control recommended by
the American Diabetes Association', due to complex reasons such as lack of motivation
and denial of the disease.
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Chapter 2. Glucose Monitoring Market Overview
2.1 The Glucose Monitoring Market
The worldwide diabetes therapeutic and diagnostic market reached $31.7 billion in 2007.
The revenues in the glucose monitoring market totaled $5.04 billion in 2003 and are
projected to reach $12.4 billion by 20108. The U.S. accounts for more than 55 % of the
global diabetes market.
The glucose monitoring market has a large and rapidly expanding customer base. In 2005,
there are about 18 million people afflicted with diabetes in the U.S. alone and the number
is projected to double by 20509. Currently about 3.2 million Type I and Type II American
diabetics need to monitor their blood glucose level one or multiple times daily by
fingerstick measurements.
In 2004, 87.8 % of revenue from glucose monitoring market was generated from the sales
of glucose strips and meters. However, this market sector is decreasing because of the
pain and discomfort associated with finger-pricking and deficiencies in intermittent
testing. On the contrary, minimally and non-invasive glucose market rises at 13% per
year, and is expected to reach $390M in 2008. New glucose sensing technologies are
focusing on minimizing cost, invasiveness and developing continuous glucose monitoring.
A large fraction of the market will respond positively to companies who are able to create
new glucose monitoring technologies and insulin delivery methods that are accurate,
continuous, non-invasive, easy to use, portable, stylish, and low-cost. Therefore, to seize
the opportunity and align to such a huge market, research and development should be
focused on developing more convenient and pain-free solutions for diabetics who
struggle to make lifestyle changes.
There are four major players in glucose monitoring market, namely Roche Diagnostic
(36 %), LifeScan (29%), Abbott Labs (28 %), and Bayers (14 %). This is a highly saturated
market with high entry barriers.
Abbott Labs
18%
others
Bayers 3%
. AAL ,
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uch Ultra:
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Figure 2.1 Maior players in Glucose Monitoring Market.
2.2 The Continuous Glucose Monitoring (CGM) Market
It has been estimated that 25,600 people in the U.S. use CGM devices, generating $21M
revenue in 200710. This includes 3% of 334,000 patients using insulin pumps and 1.5% of
the 1.1 million Type I and II diabetics who measure their blood glucose level using
lancets and do not use insulin pumps. In 2008, Medtronic has more than 52% of the
market, whereas Dexcom and Abbott have seized about 37 % and 11 %, respectively'0 .
Continuous Glucose Monitoring System (CGMS) caters to the need of the 3.2 million
diabetes patients relying exclusively on insulin therapy. As continuous glucose
monitoring is expected to be the new standard for daily glucose monitoring and benefit
millions of diabetes patients, CGMS has the potential to overtake a great portion of the $5
billion U.S. glucose monitoring market.
Chapter 3. Glucose Sensing Technologies
One way to categorize glucose sensors is based on their invasiveness. Today, the most
popular and standard glucose monitoring for diabetics (due to insulin resistance or
reduced insulin sensitivity, combined with reduced insulin sensitivity) is through the use
of glucose meters. It is a simple, accurate but invasive and non-continuous method,
mainly used for the home-monitoring of blood glucose levels. A blood glucose meter is
normally used for measuring the blood glucose level. A drop of blood is taken usually
from the fingertip and placed on a disposable test strip that interfaces with the glucose
meter. The test strips contain glucose oxidase or glucose dehydrogenase that oxidizes
glucose to glucolactone and an electrode.
Glucose sensors can also be categorized in to two major types. The first type is the
traditional monitor that provides some-time snapshots of the blood glucose. A new
generation of blood glucose sensors, known as continuous glucose monitors, delivers
readings every few minutes around the clock. This allows patients and their physicians to
constantly measure trends, chart ups and downs, and identify problems and make
adjustments to their insulin intakes.
Although each continuous glucose monitoring system is different, most of them work in a
similar way. A small, disposable sensor is inserted under the subcutaneous tissue through
a tiny flexible probe. This sensor measures changes in glucose levels in the interstitial
fluid and stores the data up to 3 - 4 days at a time.
There are currently more than 25 glucose monitoring products available on the market or
in clinical trials. Most of the commercial glucose meters employ enzyme-photometric or
amperometric biosensing technology.
Enzyme-Photometric Sensing
This technology is based on a dye-related reaction is used in first generation blood
glucose meters. Products based on this technology include LifeScan's One Touch Basic,
Roche's Accu-Chek Easy, etc. During the reaction between glucose and the enzyme, the
reduced enzyme is reoxidized by excess ferrocyanide ion. The amount of color reflected
from the strip is proportional to the concentration of blood glucose and is measured
photometrically. The overall reaction can be represented as follows 11:
glucose + GOx (oxidized) -+ gluconolactone + GO, (reduced)
GOx (reduced)+ ferriciniium' -+ GOx (oxidized)+ ferrocene
ferrocene -> ferriciniu+ + electron
These meters provide more accurate readings compared to urine glucose testing. Recent
glucose meters (e.g., Accu-Check® Active) utilizing this technology take readings within
5 to 20 seconds and require a small blood sample (1 to 3.5 pd).
Amperometric Sensing
Most of the currently available glucose meters use this second generation technology.
Glucose oxidase is immobilized at a positively charged base electrode. Electrochemical
detection of hydrogen peroxide as the product indicates the concentration of glucose. The
electrical charge generated is measured.
Glucose Oxidase
Glucose + 02 H20 2 + gluconic acid
-700 m V
H 20 2 -- 02+ 2e-
Variations in temperature may affect the readings but can be rectified by incorporating a
temperature feedback into the system. Meters based on amperometry include Accu-
CheckO Complete, Glucometer Elite, etc.
Invasive glucose sensing usually involves fingerstick testing. There are devices such as
Lifescan OneTouch Ultra® that allow users to test their glucose levels by drawing blood
from their arm (where there are fewer nerves) instead of the tips of their fingers. Some
minimally invasive continuous glucose sensors also employ enzyme based amperometric
glucose sensing (e.g., Medtronic-MiniMed CGMS®), in which the sensor can be
implanted in the subcutaneous tissue using a specialized tool designed to minimize tissue
damage. The tip of the sensor is made of a membrane selectively permeable to
glucose. At the electrode surface, hydrogen peroxide produced by the reaction catalyzed
by glucose oxidase is oxidized into water, generating a current that can be measured and
correlated to the glucose concentration outside the membrane.
There are also many non-invasive or minimally invasive glucose sensors developed based
on different underlying physical principles, such as optical sensing, ultrasound
technology, impedance spectroscopy, iontophoresis etc.
Fluorescence Technology
Light suffers reflection, scattering and transmission when it is shone on biological
specimens. It has been shown by study that fluorescence intensity generated by body
fluids when excited by laser light at certain frequency is dependent on the glucose
concentrationl2. Ultraviolet laser light at 308nm is focused on the skin. Transmission or
reflectance of light can be measured by detectors. However, the limitation of this
technology is that the fluorescence intensity is affected by other parameters such as skin
pigmentation, redness, and epidermis thickness 13. Thus, the best way to overcome these
noises is to measure the fluorescence of glucose at a frequency that is only specific to
glucose. An example of the products utilizing fluorescence technology is the glucose-
sensing contact lens developed by researchers at the University of Texas and Ciba Vision.
The contact lens measures glucose concentration in tears.
Reverse lontophoresis
This method transports glucose outward from the skin, opposite to the direction of normal
medicaments 14. An example of products utilizing this technology is the GlucoWatch G2®
Biographer which is a wrist-watch continuous glucose monitoring device, by Animas
Technology' 5 . The watch has two independent potentiostat circuits; neutral glucose
molecules, together with Na' ions, are extracted through the epidermis surface via the
electro-osmotic flow to the iontophoretic cathode. Hydrogel discs containing the glucose
oxidase constitute the electrolyte in the biosensor that detects the H20 2 generated by the
glucose oxidase-catalyzed reaction. Drawbacks of such a system include the fluctuation
in the biosensor response due to skin temperature and perspiration, time delay, skin
irritation, long calibration procedure and warm-up period. Although the U.S. Food and
Drug Administration (FDA) has approved it for an auxiliary glucose monitoring product
without replacing the invasive finger-pricking control, GlucoWatch is no longer available
in the market due to its unsatisfactory performance.
Ultrasound Technology
Photoacoustic spectroscopy (PAS) is the most used technology based on ultrasound. A
pulsating laser light is used to excite a tissue fluidl 6-19. Heat is generated when the laser
beam meets the tissue cells, causing pressure variations. The resultant acoustic signals
correlating the characteristic optical properties of blood glucose are detected through a
piezoelectric transducer. The ApriseTM from the Glucon is based on PAS. Drawbacks of
such a system include low sensitivity, high interferences and poor reproducibility.
Impedance Technology
The dielectric (impedance) spectrum of tissue can be measured by passing through
alternating currents of known intensity through it. A decrease in sodium ion
concentrations and an increase in potassium ion concentration in plasma can be induced
by variations in plasma glucose concentration. Consequently, the red blood cells
membrane potential is changed and can be estimated by determining the permittivity and
conductivity of the tissue through the dielectric spectrum. Based on this technology, the
company Pendragon commercialized a wrist glucose sensor, Pendra® in Europe in 2003
for a short period of time. However, due to the high interference levels, the calibration
process did not achieve satisfactory performance, and the post-market reliability was poor.
The product never received FDA approval.
Chapter 4. Existing Continuous Glucose Monitoring Systems
4.1 Overview
With the advances in insulin delivery technology, the demand for concurrent
development in glucose sensing technologies is rising. Most current glucose sensing
devices rely on direct analysis of blood withdrawn from the tip of a finger intermittently,
which causes much discomfort to the users and often results in missing detection of hypo-
and hyperglycemia events. The ability of a continuous insulin delivery system to
maintain normal blood glucose levels is only as good as the ability of the glucose sensing
devices to provide continuous real-time information about blood glucose level. It has
been shown that continuous monitoring of blood glucose levels and insulin
administration are capable of improving life quality of diabetes patients, and better
regulating the hyper- and hypoglycemia incidents, thereby avoiding physiological coma
and even death2o. Consequently, constant innovations in glucose monitoring technologies
are driven by factors such as non-invasiveness, accuracy, cost, convenience and more
importantly, continuous testing.
Glucose sensors must be both accurate and precise, with a high sensitivity to changes in
blood glucose concentrations. They must also have excellent biocompatibility in order to
maintain integrity and efficacy for in vivo and continuous applications. The minimally
invasive or non-invasive continuous glucose monitoring system (CGMS) will be the most
promising and ideal in vivo glucose monitoring technology.
The research on intravascular glucose sensors has being ongoing since 1960s. The
intravascular approach was deemed to be the most ideal in glucose monitoring since it
allows direct measurement of blood glucose levels. However, due to hemocompatibility
issues, thromboembolic complications and spread of infection, the clinical feasibility for
long-term intravascular glucose sensors is limited. Therefore, in the past two decades the
research focus has been shifted to the development of subcutaneously implanted glucose
sensors.
A continuous glucose monitoring system is defined as an FDA-approved device that
records glucose levels continuously throughout the day and night. The main functions of
CGM devices are to provide both retrospective and real-time information to: 1) detect
hypoglycemic and hyperglycemic events; 2) predict impending hypoglycemia events; and
3) detect glycemic variabilities. To date, 10 CGMS have been approved by FDA for use
in the U.S. or bear CE markings for use in Europe. They are:
(1) The CGMS®' by Medtronic Diabetes, Northridge, CA.
(2) The CGMS® GoldTM, by Medtronic Diabetes, Northridge, CA.
(3) The Guardian Telemetered Glucose Monitoring System, by Medtronic Diabetes,
Northridge, CA.
(4) The MiniMed Guardian® REAL-Time Continuous Glucose Monitoring System, by
Medtronic Diabetes, Northridge, CA.
(5) MiniMed Paradigm® REAL-Time SystemTM , .by Medtronic Diabetes, Northridge, CA.
(6) STS Short Term Sensor, by DexCom, Dan Diego, CA.
(7) The STS SEVENTM System, by DexCom, Dan Diego, CA.
(8) The FreeStyle Navigator®, by Abbott Diabetes Care, Alameda, California.
(9) GlucoDay®-S, by Menarini, Inc., Florence, Italy.
(10) The GlucoWatch G2® Biographer, by formerly Cygnus, Inc., Redwood City, CA.
The company was completely acquired by Johnson and Johnson and the product was no
longer on sales. It has been considered as a defunct product therefore is out of scope of
this thesis.
Combining with insulin delivery systems, CGMS is believed to be the pathway to an
artificial pancreas21.
4.2 Existing Continuous Glucose Monitoring Technologies
4.2.1 Medtronic's Continuous Glucose Monitoring Systems
The MiniMed CGMS®
The MiniMed CGMS® was the first continuous glucose monitoring device approved by
the FDA in June 1999. The sensor is a subcutaneously implanted, needle-type
amperometric enzyme positive electrode (refer to Chapter 3), with glucose oxidase
immobilized on it. By the electrochemical detection of hydrogen peroxide at the
platinum electrode, glucose concentrations in the interstitial fluid can be measured 22. The
sensor is coupled to a portable logger that records the glucose concentrations. The data
can be downloaded to a computer after up to 3-day sensing.
The interstitial fluid glucose concentrations are similar to blood glucose levels in the
steady state23 , but lag behind 5-30 minutes when glycemic changes rapidly, especially
during post-meal periods242 5 . It has been postulated that the lag is dependent on species,
sensor type and size, the applied stimulus (meal or glucose intake), the subject and the
depth of insertion into the subcutaneous tissue26
There are two other drawbacks with this kind of sensor: the unpredictable drift and the
impaired responses in vivo. Consequently, frequent calibrations against fingerstick
measurements of blood glucose concentrations are needed. For the MiniMed CGMS®,
four daily calibrations are recommended.
The clinical utility of this system has been confirmed in numerous studies comparing the
MiniMed CGMS® profiles with conventional finger-pricking methods (Fig 4.1).
Sachedina and Pickup's study in 200327 has shown that many episodes of hyperglycemia
and hypoglycemia in 18 Type I diabetic patients were missed by the intermittent finger-
pricking testing but detected by the CGMS, whereas the mean and oscillations in blood
glucose concentrations were nearly equal in both methods.
Figure 4.1: Comparison between in vivo glucose monitoring in a Type I patient using
MiniMed CGMSIR (solid line) and intermittent blood glucose testing (squares). The
results show that the mid-morning episode of postprandial hyperglvcemia is missed by
intermittent glucose testing 7.
In 2003, a second generation of Minimed CGMS" - the CGMS® System Gold (Fig 4.2),
was approved by FDA. It uses the same sensor but is equipped with more advanced
statistical modeling software to calculate and store glucose levels every 5 minutes over a
72-hour period. The range of glucose concentration measured is 40 to 400 mg/dl. The
patients are required to manually enter at least 4 blood glucose values per day.
Unfortunately, the CGMS® System Gold does not provide readings of real-time glucose
concentrations. Only retrospective information can be obtained by downloading the 3-day
data collected. Timely treatment can be then given based on the pattern of intermittent
hyperglycemia, intermittent hypoglycemia and glucose level variations. The median
average relative deviation of the MiniMed CGMS® biosensor is found to be 11-12 %.
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Figure 4.2.: The MiniMed CGMSR" Gold. A - a sensor: B - a sensor inserter, C - the
monitor; D - the monitor can be connected to a docking station and data can be
downloaded into a comnuter2 8.
The Guardian®
The Guardian® was approved by FDA on February 11, 2004. It uses the same sensor as
the MiniMed CGMS® system, and it also provides retrospective glucose concentration
data. There are two significant differences between the two systems: firstly, the sensor
and monitor in the Guardian® are connected by a wireless transmitter; secondly, the
Guardian® contains a real time alarm which provides audible alerts if the glucose level
exceeds the limits preset by the user. Nevertheless, the Guardian® does not display real
time glucose readings. The diabetic patient is recommended to check his/her blood
glucose level by the traditional finger-pricking method and act based on that reading
when the alarm for hypo- or hyperglycemia occurs. In the event of a hypoglycemia alarm,
there is a tradeoff between the sensitivity and specificity of the sensor. Highly sensitive
sensors are likely to generate false alarms, whereas in the case of high specificity, some
hypoglycemic events may be missed.
This device was never commercialized. It offered the fundamental concept for the
development of the Guardian® REAL-Time CGMS.
The Guardian" REAL-Time CGMS
This product was approved by FDA on June 11, 2005 for adult diabetics. It resembles the
Guardian®, but the monitor displays real time glucose levels every 5 minutes (Fig 4.3).
Up to 21 days of the continuous glucose data can be stored and conveniently downloaded
into a computer anytime.
Figure 4.3: The GuardianR RT Monitor Screen. A - the glucose reading: B - an alarm
warning; C - trend arrows for glucose levels; D - a trend graph displaying recent
patterns of glucose levels28.
The real time glucose readings allow the patients to act proactively to recover from and to
prevent hypoglycemia and hyperglycemia events, thereby reducing the glycemic
variability, which is believed to be a risk factor in developing long-term diabetic
complications.
The MiniMed Paradigm® REAL-Time Insulin Pump and CGMS
Being approved on April 13, 2006, it is the world's first and only system that integrates
an insulin pump with a real-time CGMS (the Guardian" RT)29. It is not a closed loop
system. The MiniMed Paradigm® REAL-Time 522 or 722 insulin pump is built on the
MiniMed Paradigm® platform and can work independently; the optional real-time CGMS
offers real time glucose readings, safety alarms and glucose trend data. Users are
recommended to calibrate the sensor against a fingerstick measurement every 12 hours
(preprandial and at night). Another feature of this product is that the transmitter can store
40 minutes of readings in case the connection to the receiver is interrupted or broken.
Figure 4.4: The MiniMed Paradigm REAL-Time Insulin Pump and CGMS29
The greatest advantage for the Guardian® RT and the Paradigm® REAL-Time insulin
pump and CGMS is that they have been approved by FDA for Type I and II patients
above 7 years old. To date, they are the only CGMS that can be used by children, who
make up a group that could benefit the most from continuous glucose monitoring.
Another advantage is that the calibration can be done with any glucose meter.
On the other hand, the MiniMed Paradigm® REAL-Time insulin pump and CGMS has
the most expensive initial device cost and replacement transmitter sets ($999 with 10
sensors). The transmitter requires charging, and has a short lifespan of one year only.
4.2.2 DexCom's CGMS
The DexCom STS CGMS
The DexCom STS CGMS was approved by FDA in March, 2006 (Fig 4.5a). The system
has four parts: a sensor designed to last for 72 hours, a battery operated transmitter that
4%m*52 ew 2
needs to adhere to the skin by a support mount which is not water proof, a rechargeable
STS receiver that looks like a cell phone, and a One Touch Ultra glucose meter with a
download cable. Glucose oxidase is immobilized at the tip of sensor which is inserted
into the subcutaneous tissue via a dedicated Applicator. The sensor needs to be replaced
every three days but the STS transmitter and Receiver are reusable. The CGMS has the
software - DexCom DM Consumer Data Manager for retrospective extraction and
analysis of glucose data. Calibration needs to be carried out every 12 hours. The glucose
levels are measured every 5 minutes. Limits for hypo- and hyperglycemia alarms can be
manually set.
Compared to Medtronic's CGMS, DexCom STS CGMS has a smaller insertion needle
(25 gauge versus 22 in MiniMed Paradigm RT in Guardian RT); the sensor length is also
shorter. Unlike Medtronic's CGMS, the calibration in STS CGMS must be done using
One Touch Ultra and no manual input is allowed. The mean absolute difference is 26%
for STS CGMS, much higher than the 19.7% in Medtronic's CGMS.
The DexCom SEVENTM System
In June 2007, FDA approved DexCom's STS SEVENTM system, as the sensor can be
used up to seven days before replacement. The system consists of 3 parts: an even smaller
sensor with the smallest insertion needle of 26 gauge, a wireless transmitter that is water
resistant30 up to 3 feet for 30 minutes, and a receiver that stores up to 30 days of data. The
receiver can display a 1, 3 and 9-hour glucose trends and current glucose readings every 5
minutes.
The greatest advantage of DexCom SEVENTM CGMS is its longest sensor life that
significantly reduces the expenses. It also has the lowest initial cost, and a better accuracy
than the DexCom SEVEN. Moreover, the system is reported to give rise to the least skin
irritation. However, some drawbacks associated with this system are that the alarm for
hypo- and hyperglycemia has limited range, the receiver needs to be charged every 2 to 3
days, downloading of data is slow, and calibrations must be done with Ultra glucose
meter via cable connection.
Figure 4. 5(a): DexCom's STS CGMS: (b) DexCom's STS-SEVEN CGMSo0.
4.2.3 Abbott's FreeStyle Navigator"
This CGMS was approved just recently (March, 2008). The system is designed to
measure glucose levels using amperometry intermittently or continuously (Fig 4.6). The
sensor contains glucose oxidase, and is to be implanted into the subcutaneous tissues in
the back of the upper arm or abdomen at a 90 degree angle to the skin surface by a
disposable insertion device. Glucose levels in the interstitial fluids are measured 31. The
sensor life is limited to 5 days.
I 1
Figure 4.6: The FreeStyle Navigator' '31
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The FreeStyle Navigator" CGMS has its unique Wired EnzymeTM  Technology
(Therasense, Alameda, CA). The problems of using platinum working electrode which is
prone to interference by ascorbic and uric acids, and the redox reaction that suffers from
variations in oxygen concentration are solved by the application of osmium based
mediators immobilized on carbon electrodes. Glucose is directly electro-oxidized, and
electron transfer is achieved by 'electron-hopping' between the osmium centers, thus
'wired' to the electrode. This approach has demonstrated minimal oxygen dependence
and insensitivity to interferents, and has been claimed to be more accurate31 .
The FreeStyle Navigator® CGMS offers diabetics some key advantages over the others:
the system measures and reports glucose levels every minute. The sensor and transmitter
are designed to accommodate showering, swimming and other normal physical activities
(therefore the name "FreeStyle Navigator"). The insertion is much less traumatic
compared to the good-sized needle on the Minimed. Another special feature is that the
Abbott's FreeStyle Navigator® is the only CGMS on the market that has a build-in blood
glucose meter for calibration purpose. In addition, the FreeStyle Navigator can be
calibrated with any meter. Moreover, it has the least mean absolute difference, longest
transmitter life, highly customisable alerts as well as the greatest signal range. The
advanced algorithm in the Co-pilot software gives users alerts 30 minutes before any
hypo- or hyperglycemia excursions.
One drawback of the FreeStyle Navigator® CGMS is that FDA only approved it to be
used by adult patients, age 18 and over. Moreover, the sensor requires the longest warm
up period of 10 hours.
The FreeStyle Navigator® CGMS will be available in the U.S. market in 2008. It has
obtained CE Mark in June 2007 and is already available outside the U.S.
4.2.4 Menarini's GlucoDay-S
The GlucoDay-S 32 is developed and marketed in Europe by Menarini, Inc, a French
company. It has not yet been approved by FDA. Being the only commercialised CGMS
that does not use an implanted sensor, the minimally-invasive GlucoDay-S CGMS makes
use of a microdialysis process to pump a continuous flow of perfusion fluid through a
microdialysis system. A microfiber with a diameter of about 100lpm is inserted into the
subcutaneous tissue in the abdominal wall. The system also contains two small bags of
crystalloid fluid 33. A perfusion fluid is pumped from a buffer bag into the subcutaneous
tissue through the microfiber and rinses the interstitial fluid. The interstitial glucose
concentrations in the effluent dialysis filtrate are then measured by the device with an in-
line biosensor coated with a glucose oxidase and a polycarbonate membrane. Another
bag contains the waste fluid after the dialysis process. Different flow rates controlled by
the programmable micropump are used: the faster rate is used for filling and washing the
interstitial fluid, the slower for the feeding of the microfiber. The bags can be contained
in a small pouch and worn conveniently as a belt (Fig 4.7).
Figure 4.7: An Illustration of the working principle of GlucoDay-S CGMS*2.
The GlucoDay-S CGMS provides both real time and retrospective information wirelessly.
The device displays result every 3 minutes and incorporates safety alarms for hypo- or
hyperglycemia events. Unlike other commercial CGMS, it only requires 1 daily
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calibration34. Studies have shown that GlucoDay-S was more accurate than MiniMed
CGMS GoldTM 35, with or without corrections for the lag between interstitial glucose
levels and the blood glucose levels..
Nevertheless, there are some drawbacks associated with the system. The microfiber must
be replaced every 48 hours, adding to the expenses. Also, the system is unable to provide
real time trends of glucose levels.
4.3 Comparison of Existing CGMS
In this section, various aspects of currently available CGMS - MiniMed Guardian®
REAL-Time CGMS (used individually as well as in MiniMed Paradigm® REAL-Time
System Insulin Pump and CGMS), DexCom STS SEVENTM , FreeStyle Navigators and
GlucoDay-S will be compared. Tables in Appendix A give a summary of the comparison.
4.3.1 Accuracy
It is challenging to determine the accuracy in CGMS, since they operate in the interstitial
fluids and face problems of sensitivity, stability, calibration and time lag. It is important
to assess the accuracy of CGMS by using numerical and clinical metrics, since there are
statistical difficulties in using the traditional correlation or regression due to the nature of
the structure of CGMS data points43. Numerical accuracy shows the closeness between
the CGMS readings and the corresponding reference blood glucose measurements.
Clinical accuracy is used to assess the impact of sensor errors on treatment decisions
based on CGMS output.
It was found that the numerical accuracy of the Guardian® RT, FreeStyle Navigators and
GlucoDay was comparable44. The FreeStyle Navigator® has advantage in detecting
hypoglycemia. The numerical errors of the DexCom STS were greater. For clinical
accuracy, the four sensors had similar results in euglycemia region; the FreeStyle®
Navigator and GlucoDay-S have better accuracy in hypoglycemia regions (Table A-1).
4.3.2 Sensors
The features of the sensors are summarized in Table A-2.
All exising CGMS measure glucose levels in interstitial fluids using amperometric
biosensing technologies. GlucoDay-S is the only CGMS that does not use an implanted
sensor. MiniMed Guardian® RT CGMS and FreeStyle Navigator® have comparable
sensor length and size; DexCom STS SEVENTM has the smallest sensor probe (26 gauges)
and a shorter sensor45. It also has the longest sensor life - 7 days, approved by FDA;
followed by 5 days in FreeStyle Navigator®. MiniMed Guardian® RT has only been
approved for 72 hours, though some users have reported longer usage. GlucoDay sensors
must be replaced every 48 hours. Freestyle Navigator® requires the longest initialization
time - 10 hours, but it measures the widest range of glucose concentrations.
In terms of calibration frequency, GlucoDay is the best as it only requires a one-time
calibration per sensor, whereas MiniMed Paradigm" and DexCom SEVEN TM require the
most frequent calibrations.
4.3.3 System Configuration
The system configurations of existing CGMS are summarized in Table A-3. Among all
four CGMS, only the MiniMed Guardian® RT is able to communicate with its insulin
pump. FreeStyle Navigator" measures the glucose level most frequently - once every
minute. Other CGMS takes measurement every 3-5 minutes. All CGMS except
GlucoDay-S display trends of glucose level changes, and incorporate alarms for hypo-
and hyperglycemia events. The range of transmission is longest for FreeStyle Navigator*.
The transmitter lifetimes of MiniMed Guardian" RT, DexCom STS SEVENTM and
FreeStyle Navigator® are 1 year, 6 months, and 2 years respectively.
4.3.4 Cost Analysis
The price of each CGMS is shown in Table A-4. Figure 4.8 below shows the result of
cost analysis. The analysis considers the annual expenses on CGMS including the cost of
device, glucose sensors, and transmitters that need replacement.
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Figure 4.8. Cost analysis of CGMS.
It can be seen clearly that MiniMed Paradigm® RT insulin pump and CGMS and
FreeStyle Navigator® incur about the same annual cost of around $5000. DexCom STS
SEVENTM is the most cost effective among the four due to its longer lifetime, but the c6st
still approaches $3600. The high cost is obviously a burden to diabetes patients,
especially if insurance coverage or reimbursement is not available.
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Figure 4.9: CGMS and Disposable Revenue in U.S. CGM Market.
Figure 4.9 shows the revenue generated from the CGMS and disposable sensors in the
U.S. continuous glucose monitoring market from 2005 to 2009 (expected value from
2007 onwards). Before 2006, Medtronic was the sole player in the CGM market.
Immediately after Dexcom STS entered the market in March 2006, it was able to capture
and maintain a significant portion of the market share, probably due to its low cost and
longer sensor life, especially after the introduction of DexCom SEVENTM in June, 2007.
FreeStyle Navigator® is expected to seize 11% of the market in 2008 and increase its
market share to 16 % in 2009, indicating that its relatively long sensor life and high sensor
accuracy are preferred features. However, FreeStyle Navigator" may not be able to
capture a very large portion of the market due to the high cost incurred. Meanwhile,
Medtronic is expected to maintain its leading position in the market, indicating that the
MiniMed Paradigm® integrated system is an attractive feature.
From this cost analysis, we can infer that important factors driving the continuous
glucose monitoring market are the cost, sensor life, and the ability to integrate with
insulin pumps.
This brief cost analysis only serves as a reference, as many diabetes patients use glucose
sensors for a much longer period than indicated by the user manual to cut down the cost.
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4.3.5 Status of CGMS
GlucoDay-S has not been approved by FDA and is only available for purchase in some
European countries such as Austria, Belgium, Italy, France, Germany, Greece, the UK,
Portugal, Spain, and the Netherlands. The other CGMS have been approved by FDA and
are available across the United States. MiniMed Guardian" RT and Paradigm ® RT insulin
pump and CGMS are available in Europe and India, and seven cities in America.
The CGMS companies are working towards their next generation products: Medtronic is
having its closed loop sensor and pump in clinical trials; DexCom is trying to improve its
implantable sensor life to 1 year for long term usage; Abbott is also integrating its CGMS
with insulin pump.
4.4 SWOT Analysis for Existing Continuous Glucose Monitoring Systems
4.4.1 Strengths of CGMS
There is no doubt that the greatest advantages of CGMS are the vastly higher density of
information they can provide than the episodic monitors, and the better detection of hypo-
and hyperglycemia events, such as post-prandial peaks. Intermittent glucose monitor
often miss significant fluctuations. It has been reported that with the traditional
intermittent glucose monitoring, optimal control of glucose levels (90-130ml/dL) is only
achieved for less than 30% of the day36. On the contrary, recent clinical trials have
proven that using CGMS can decrease the time spent in hypo-/hyperglycemic ranges,
increase the amount of time spent in the euglycemic range, and yield less glycemic
variability. Moreover, episodic glucose testing does not forecast trends of future glucose
levels, but a continuous monitor do have the predictive capability with fair accuracy.
Consequently, with information about the direction, magnitude, duration, frequency and
causes of fluctuations in blood glucose levels, CGMS can help diabetics achieve much
better blood glucose control and facilitate the making of optimal treatment decisions,
thereby significantly reducing the risks of developing long-term complications associated
with diabetes. When glycemic patterns are poorly understood, and when retrospective
patterns are required to adjust therapy, CGMS offers advantages over intermittent glucose
monitoring.
Furthermore, it requires less manual or mental effort to operate a continuous glucose
monitor than an intermittent one, since the measurement and analysis are done
automatically by the CGMS. As a result, dosing errors and less than optimal blood
glucose control can be reduced. In the case of the MiniMed Paradigm® REAL-Time
Insulin Pump and CGMS, the system not only recommends proper insulin dosages, but
also actually automatically delivers them. Better self-management can be achieved.
Last but not least, all currently available CGMS are minimally invasive, greatly reducing
the pain experienced by fingerstick testing.
4.4.2 Weaknesses of CGMS
There are a number of disadvantages to continuous glucose monitoring. Firstly, none of
the currently available CGMS can provide glucose measurements that are sufficiently
accurate or reliable to replace the traditional fingerstick measurements. This is because
current CGMS measures interstitial glucose concentrations that are similar to blood
glucose levels in the steady state, bug lag behind when glycemia is changing rapidly.
Biofouling is another important reason for the degradation in accuracy and lifetime of
sensors. It has been reported that the accuracy of all commercially available CGMS is the
lowest in the hypoglycemic range, which is where there is a great need for sensitivity and
specificity in terms of serving as an alarm for hypoglycemia. The average discrepancy
between CGMS and episodic measurements is about 15%. Therefore, measurements from
CGMS cannot replace blood glucose measurements. In fact, when using any of the
commercial CGMS, diabetes patients are recommended to confirm with a blood glucose
meter measurement before making therapeutic adjustments, especially when alerts of
hypo- or hyperglycemia events take place.
Moreover, CGMS are costly. The initial costs of the monitors and transmitters are around
$500-1000, depending on the system. The disposable sensors that have to be replaced
once or twice a week are at a cost of $35-$60 each. This makes the annual cost of sensors
reach above $2000. A greater disadvantage is that CGMS are not always afforded by
reimbursement, though diagnostic 72-hour CGMS might be covered by insurance with
appropriate justification. Furthermore, due to the complex nature of the monitoring
device, both healthcare providers and diabetes patients are required to be trained in sensor
use and trend interpretation. This further adds to the effort and thus the cost to the overall
spending.
Although current CGMS are categorized as minimally invasive as the sensors
compromise the skin barrier but do not puncture any blood vessels, and the sensors are
usually very small, wounds are still created when the sensors are inserted into the
subcutaneous tissue, resulting in possible side effects such as allergic reactions or
infection. When the sensor needs to be replaced, new wound is created during the next
insertion. Fingerstick calibrations must be performed a couple of times daily, therefore
the patients are still not relieved from the invasiveness. The calibration time is usually
long, and must be performed when the blood glucose level is steady.
4.4.3 Opportunities for CGMS
The opportunities for CGMS are related to the deadly long-term complications brought
by the incurable diabetes and the rapidly growing diabetes population. Diabetes
downgrades quality of life, and also imposes an enormous economic toll both on the
individual and on society. The effects of CGMS brought in reducing the risks of
developing the long term complications and improving the quality of life significantly
improve both lifestyle and lifespan of the diabetes patients.
Diabetes is the largest self-test market for medical diagnostic products in the world. The
potential customer base for CGMS is very large and growing rapidly. The population is
diabetics is increasing due to population growth, aging, urbanization and increasing
prevalence of obesity and physical inactivity". It is estimated that there will be more than
366 million diabetes patients being diagnosed worldwide in 2030; 33% of the people with
Type I or II diabetes must have insulin delivered by injection or a pump.
A much greater population is estimated to be pre-diabetic, or at increased risk for
developing diabetes in the future. Nearly 57 million Americans are estimated to be pre-
diabetic, and they are progressing towards Type II diabetes at about 10% per year.
Managing the blood glucose levels in these people is also important. As CGMS advances
and achieves better accuracy and user compliance, and lower cost, more and more
diabetes patients who are aware of continuous glucose monitoring will adopt CGMS
more readily. Thus, the long-term market opportunity for CGMS is promisinglo
4.4.4 Threats for CGMS
Current CGMS are minimally-invasive, with sensor lifespan of 3 to 7 days. Therefore,
they are subject to competitions from the development of non-invasive continuous
glucose monitors, as well as totally implanted or intravascular CGMS with a longer
sensor life.
Currently diabetes is still an incurable disease, at least for Type I patients. However,
advancement in the development of artificial pancreas and the progress in pancreas
transplantation and advanced medicine might reverse the situation. Although this is
highly unlikely to be achieved in short term, it poses a future threat to current CGMS.
Thirdly, the reimbursement issues could slow the deployment of CGMS. Significant
investment in large, randomized clinical trials to isolate and quantify the improved
patient outcomes by using CGMS is required for CGMS to receive broad-scale coverage
as an outpatient device. Moreover, even for a CGMS that is covered or properly
reimbursed, it is still difficult to be accepted for clinician adoption, which is critical since
CGMS is administered by clinicians or by physician prescription. Some of the key issues
involved are time limitations, payment-based limitations, as well as the poor adherence to
clinical guidelines38
Last but not least, the successful use of CGMS highly depends on active patient self-
management, which can be retarded by a number of fundamental barriers, such as lack of
access to health insurance, poor socioeconomic status, insufficient education on how to
translate the information into treatment, and inadequate patient input and involvement in
the product design process. Significant incentives and resources are needed for diabetics
to overcome these barriers to achieve quality health care.
Chapter 5. Continuous Glucose Monitors in Development
Driven by the huge potential glucose monitoring market, there has been always much
hype in the development of new continuous glucose monitoring systems. This chapter
will focus on some of the most promising continuous glucose monitoring systems, which
are still in development or commercialization process.
5.1 OrSense NBM-200G non-invasive CGMS
OrSense Ltd39 is a medical device company based in Israel. In June 2006, its NBM-200G
based on the well-patented Occlusion Spectroscopy technology received the technology
innovation award from Frost & Sullivan. European CE mark was granted in June 2007.
The occlusion spectroscopy technology is a non-invasive optical measurement method. A
ring-shaped probe is placed around the patient's finger. By applying a gentle pressure to
the finger, the blood flow is occluded temporarily. Optical sensing is performed by
measuring the light transmitted through the finger during this occlusion period and a
tissue signal is obtained (Fig 5.1). When the pressure is removed and the blood flow
restores, a second measurement is made, generating an optical signal for blood.
Difference spectra calculated thereby eliminates the effects of bone, other tissues and
nonpulsatile blood. This yields a high signal-to-noise ratio that is completely blood
specific. Blood glucose levels, haemoglobin, as well as other analyte concentrations can
be measured by analyzing the signals. Calibration is needed for glucose predicting
parameters using four blood glucose reference points in the first three hours, and an
additional reading after 8 hours. It has been shown that the NBM-200G exhibited
comparable accuracy to invasive home testing of blood glucose concentrations on over
350 subjects.
Figure 5.1 The OrSense NBM-200G CGMS3 9.
The key advantages of the OrSense NBM-200G are its non-invasiveness, ease of use, and
pain-free, quick and safe measurements 40. Moreover, it identifies glucose trends and
detects hypo- and hyperglycemia events. However, NBM-200G is too still bulky to be a
portable CGMS and is currently only used as a clinical device.
OrSense has fully protected its occlusion spectroscopy technology by compiling an IP
portfolio of 32 granted and accepted patents in the US, EU, China and Japan, with 24
more in process. The company with its NBM-200G is actively involving in clinical trials
in the U.S. to seek FDA approval and plans to enter the glucose monitoring market in late
2008. Meanwhile, OrSense is developing its second generation monitor (Fig 5.2) that is
much smaller and perfectly portable, and is able to monitor glucose levels both
continuously and intermittently. If successful, it will be the first commercialized non-
invasive CGMS in the world.
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5.2 The SMSI" Glucose Sensor
Sensors for Medicine and Science, Inc.® (SMSI®), is a medical device company located
in Germantown, Maryland. The company is developing an optical-based glucose sensor
which is small enough to be implanted into the fatty layers under the skin and is designed
to measure interstitial glucose concentrations automatically every few minutes
continuously41. A tiny light-emitting diode with a separate photodiode receiver are
encapsulated into a pill-shaped structure about the size of a medicine capsule. Wireless
communication between the sensor and external watch reader, rate of change of glucose
levels and alerts for impending hypo- or hyperglycemia are some of its features, which
are standard for currently available CGMS.
This technology is based on competitive binding of protein to a fluorophore, for example,
Single Walled Carbon Nanotube (SWCNTs) 42. The fluorophores are conjugated with
glucose derivative to which a glucose-specific protein will bind. The binding of protein
on fluorophores attenuates their fluorescence behavior. In the presence of glucose, the
preferential binding between the protein and glucose shifts the equilibrium binding such
that fewer fluorophores are being bonded and the overall fluorescence intensity is
increased. Figure 5.3 depicts the working principle of such a sensor.
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Figure 5.3 Working Principles of Optical-Based Glucose Sensors.
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The most prominent feature of such a glucose sensor is that it is wholly implanted, and
sensing is non-invasive after implantation. SMSI® also claims that its glucose monitor is
accurate since no sampling is required and the risk of user error is reduced consequently.
Moreover, if the right fluorophores are chosen, the sensor should have excellent
specificity for glucose. No calibration against fingerstick testing is required prior to
glucose measurement, since the sensors are calibrated in the manufacture and integration
process. Furthermore, since the sensor works in a reversible equilibrium condition, no
chemicals are consumed or produced in the process and lifetime of such a sensor is
significantly longer. In fact, SMSI ® claims that its glucose sensor may work in vivo for 6
to 12 months.
Despite of the much hype in optical detection of glucose concentrations, SMSI®'s optical
sensors suffer from some drawbacks:
(1) The major concern is the biofouling (foreign body encapsulation). This can be
improved by incorporating antigenic factor into the glucose sensing unit but is
difficult to be eliminated. Biofouling is the main factor that limits the lifetime of the
sensor.
(2) A sophisticated statistical model is needed for accurate reading of blood glucose
level. There are many noises in the output readings resulted from:
* The effect of ambient light, which can be reduced but not eliminated, on the optical
sensor.
* Variations in laser excitation due to the interaction between emission light and
environment and skin surface. Temperature and humidity are two important factors
that affect the stability of the emission. Condition of the skin also affects the
penetration of emission and varies in person.
* Variations in fluorescence collection by the detector array due to the same factors
above.
* Variations in fluorescence in-vivo, i.e. due to interaction between body fluids and the
fluorophores, and attenuation of fluorescence intensity by body fluids.
(3) The most difficult hurdle for such a glucose sensor is the choice of indicator system.
It is very challenging to find the optimum non-toxic fluorescent chemical that is
specifically responsive to glucose, and fluoresces over a desired concentration range
of glucose.
(4) The intrinsic fluorescence of the indicator system due to incident radiation, which
may result in high noise levels in the output signal, needs to be attenuated.
(5) Many diabetes patients have expressed their reservations about in vivo CGMS.
Unless the sensor is completely safe, and sufficiently accurate to replace the
fingerstick testing, it would be difficult for such a product to seize the market.
SMSI® has over 30 issued and pending U.S. patents in the filed of optical-based sensors.
It has finished feasibility test and the chip design, and is currently performing pre-clinical
studies on the low cost glucose sensor.
5.3 MicroCHIPS CGMS
MicroCHIPS, Inc is a private company founded in 1999 headquartered in
Massachusetts 46. Its core technology is the well-patented microreservoir arrays, which
can protect and release chemicals in a controlled and timely manner47 . Enzymes for
glucose sensing can be stored within these reservoirs, thereby significantly lengthening
the lifetime of implantable glucose sensors. MicroCHIPS is currently developing its long-
term continuous glucose monitors using preprogrammed microprocessors, wireless
telemetry and sensor feedback loops. The competitive advantages of such a CGMS are
that the glucose sensors are both long-lived and more reliable. The detailed information
on this technology is confidential.
5.4 Risk Factors in Commercializing New CGMS
A number of key factors lead to uncertainty in commercializing future continuous
glucose sensors that are still under development:
Technological uncertainties: There are many technological barriers that limit the
lifetime of glucose sensors. The main concerns are the biofouling of the in-vivo device
and the accuracy of a sophisticated statistical model, which is essential to filter out
various kinds of noises. Animal and clinical tests need to be conducted for FDA approval.
Uncertainty in raising additional capital: Given the capital intensive nature of the
company's operations and the limited sources of revenue, the company will require
external sources of financing in order to maintain its operation. The company's ability to
raise additional funds in the next few years is not certain.
Uncertainty from strategic partnerships: It is necessary for small companies to
establish strategic alliances with larger biotechnology or pharmaceutical companies in
order to develop and commercialize medical products, given the extremely competitive
nature of the market. There is no certainty that the company will be able to establish such
alliances, that any such license agreements will be on terms favorable to the company, or
that these alliances will be successful in bringing profitable products to market. In
addition, there is potential for conflicts of interest between the company and strategic
partners that may have a materially adverse affect on the company's operational and
financial positions.
Uncertainties arising from competition: The glucose monitoring market is a heavily
saturated market is extremely competitive. Other biotechnology and pharmaceutical
companies are also actively pursuing the development of minimally/noninvasive glucose
monitoring products. Furthermore, big player competitors have greater capitalm, human
resources and experiences, placing new market players at a possible competitive
disadvantage.
Uncertainties arising from patents and proprietary rights: The ability to capture
value from the novel diagnostics and treatment technologies and to raise capitals will
depend upon the ability to protect its existing intellectual property rights and to expand its
intellectual property portfolio.
Uncertainties arising from government regulation: The future profitability will depend
upon FDA approval of new medical applications submitted by the company and its
strategic partners. There is no certainty of receiving such approval, or of the timing of
approval following submission.
Chapter 6. Intellectual Property Rights
Intellectual property (IP) is the corner stone for biomedical device companies due to the
huge economic benefits involved. A strong intellectual property portfolio increases the
value of the technology or products, thus is crucial for these companies to set a
significant entry barrier for its competitors, to develop valuable strategic alliances and
joint ventures, and to avoid potential legal liabilities.
Almost all biomedical device companies choose to protect their intellectual properties by
investing intensively in filing patents in the U.S. and other major areas in the world. "A
patent for an invention is the grant of a property right to the inventor. Generally, the term
of a new patent is 20 years from the date on which the application for the patent was filed
in the United States. The right conferred by the patent grant is, 'the right to exclude
others from making, using, offering for sale, or selling' the invention in the United States
or 'importing the invention into the United States.'"
The IP rights of all existing continuous glucose monitoring systems are well protected.
For example, before the FDA approval of its STS CGMS in 2006, DexCom already had
an IP portfolio consisted of 8 issued U.S. patents, 9 patents licensed exclusively, and 61
pending U.S. applications related to continuous glucose monitoring technology. Abbot
has 43 issued patents for its FreeStyle Navigator", covering areas from broad design
concepts to detailed system configuration. A summary of issued patents of Medtronic
MiniMed Paradigm® REAL-Time insulin and CGMS, DexCom SEVEN and Abbott's
FreeStyle Navigator" is given in Appendix B.
The patent application date is very important, as it sets the actual twenty years lifespan of
the patent. Biomedical companies normally publish patents that cover aspects as broad as
possible first, and file subsequent patents with specific details to increase the duration of
coverage for their IP rights. For instance, Abbott Laboratories filed three patents (U.S.
i Patent Section - United States Patent and Trademark Office
Patent 5262035, 5264104, 5264105) on enzyme electrodes in 1989 and 1993. Subsequent
patents went into specific details of subcutaneous glucose monitoring with frequent
updates: U.S. Patent 5593852, 5965380, 6162611, 6329161, 6514718 on subcutaneous
glucose electrodes; 6143164, 6338790, 6461496, 6486046, 6591125, 6749740 on
biosensors, etc. By building a strong portfolio, companies try to protect their IP rights in
order to achieve maximum economic benefits.
Despite the intensive effort to safeguard the intellectual property rights, there are still
expensive and time consuming legal wars going on in the field due to the extremely
lucrative nature of the business. For example, on August 11, 2005, Abbott Diabetes Care,
Inc. filed a patent infringement lawsuit against DexCom, seeking a declaratory judgement
that the DexCom STS CGMS infringes certain patents held by Abbott. The lawsuit is still
going on. Any claims of infringement or misappropriation claim could incur significant
cost to either party, strain financial and managerial resources, and impair the ability of the
company to compete against competitors. The outcome of such litigation to enforce IP
rights, copyrights, trade secrets or trademarks is highly unpredictable.
Glucose monitoring is a highly competitive and rapidly changing market. The capability
to protect a company's patented and registered, as well as unpatented and unregistered IP
rights is crucial for its survival and success. For companies with emerging continuous
glucose monitoring technologies, such as Sensors for Medicine and Science, Inc and
MicroCHIPS Inc, it is very important for them to build a strong IP portfolio, as any
claims of infringement or misappropriation of IP rights by other companies may provoke
an interference with company's pending applications, and always result in a delay or
change in company's strategic plans and substantial monetary damages. Sensors for
Medicine and Science, Inc. has been doing well in building its IP portfolio (Table B-4).
The company already has 17 issued patents since late 2001, covering aspects such as
indicator systems, methods to extend the lifespan of sensors, algorithm to calculate the
glucose level, device design in optical glucose sensing technologies.
Chapter 7. Conclusions
The glucose monitoring is a $6 billion worldwide market in 2007, with a possible
substantial expansion given the great number of undiagnosed or pre-diabetic patients.
Given the potential economic benefits associated with the huge market, as well as the
chance to help millions of people afflicted by the incurable menacing disease, the hype in
the development of CGMS will continue.
As the continuous glucose monitoring technologies advance, the weaknesses of such
systems such as inaccuracy and requirement of confirmatory fingerstick tests will be
overcome. Reimbursement and insurance issues will be solved. It is highly likely that
CGMS will eventually become a routine part of diabetes management, not only for
patients with hard-to-control blood glucose levels, but for most patients with diabetes.
Combination of CGMS real-time reading with confirmatory episodic tests will give way
to primary use of CGMS without the fingerstick tests.
Accuracy, biocompatibility as well as sensor lifespan are some major hurdles before any
non-invasive or intravascular CGMS reaches the commercial marketplace. Intensive
research and development effort is spent to overcome these barriers, by both existing and
new market players. It is highly possible that biocompatible non-invasive CGMS with a
long sensor life and high accuracy can be realized in the near future.
The future of CGMS would be an artificial pancreas - an automated fully closed-loop
insulin delivery system that regulates blood sugars like the beta cells. The development of
new insulin complex will delay gastric emptying and food absorption, and helps to reduce
both post-prandial hyperglycemia and nocturnal hypoglycemia. The success of the
artificial pancreas will highly depend on the integration of a robust continuous glucose
monitor and a mature control algorithm that would drive the insulin delivery system.
Before the realization of such a artificial pancreas, the non-invasive CGMS measuring
the subcutaneous interstitial glucose concentrations still remains the most promising
approach in diabetes management.
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Appendix A - Comparison of 4 CGMS
Table A-1i: Comparison of Accuracy of Existing CGMS.
MINIMED
PARADIGM'
REAL-TIME
CGMS/
NUMERICAL
Median Abs,
Relative Difference
(MARD) in Euglycemia
Region (%)
MARD in
Hypoglycemia Region
(%)
11.80
CLINICAL ACCURACY
CG-EGA - Euglycemia 98.9 in A 4B, 98.3 in A 4-, 98.6 in A -B, 93.7 95.5 in A 4B,
91.3 inA 91.3 in A inA 84.4 in A
CG-EGA - 84.4 in A 4-tB, NA 97 in A -tB, 95.5 in 96.2 in A -B,
Hypoglycemia 81.9 in A A 87.3 in A
Table A-2: Comparison of Sensors in Existing CGMS.
MINIMED
PARADIGM* DEXCOM STS FREESTYLEREAL-TIME CGMS/ SEVEN NAVIGATOR® GLUCODAY-S
GUARDIAN* RT
Abdomen, upper Abdomen, the
Sensor Location thigh, upper Abdomen back of the upper In-vitro
buttock arm
Sensor Lifespan(hr) 72 168 120 48
Length of Sensor 14mm 13mm 6 mm NAProbe (mm)
Gauge of Sensor
23 26 NA 18Probe
Angle of Sensor
Insertion (degrees)
Sen-serter, or DexCom STS DisposableInsertion Device manual insertion Applicator inserter with each NAmanual insertion Applicator
sensor
Sensor Warm-up
(hr)2 2 10 2-6
Calibrate at 2, 8, Calibrate every Calibrate at 10,
Calibration and then every 12 12 hours. Tice 12, 24 and 72 1 time calibration
hours. within the first 30 hours after per sensor
mins. insertion with
Range of
measurement 40-400 mg/dL 40-400 mg/dL 20-500 mg/dL NA
13.30
13.80 22.50 7.40 15.60
18.40 10.70
Table A-3: Comparison of System Configurations of Existing CGMS.
MINIMED
PARADIGM*'  DEXCOM STS FREESTYLEFEATURE REAL-TIME CGMS/ SEVEN NAVIGATOR® GLUCODAY-S
GUARDIAN' RT
Micropump and
MiniLink, Sensor, wireless Sensor, wireless a biosensor
Components transmitter, transmitter, transmitter, coupled with a
receiver receiver microdialysis
monitor
system
Communicates with
Yes No No No
an Insulin Pump
Sensor the size ofBody Surface Size Sensor the si2.05" x 1.23"
a nickel. 1.5" x .9" x .4",Covered by Transmitter is weight 0.24 oz x .43", weight NA.
Transmitter/Sensor 0.48 oz
1.4" x 1.1" x 0.3
MeasurementMeasure nt Every 5 min Every 5 min Every 1 min Every 3 min
Frequency
Display Trends Yes Yes Yes No
Display Rate of Yes Yes No NA
change
Alarms Yes Yes Yes Yes
Transmitter Yes Yes Yes NAWaterproof
Watch battery.Transmitter Batteries Rechargeable, Rechargeable, Watch batteryTransmitter Batteries Nrlaebl Replace every NANon-replaceable non-replaceable month.month.
Transmitter lifetime 1 Year 6 Months 2 years NA
Range of monitor to 6 feet 5 feet 10 feet NA
transmitter
Carelink' M  DexCom DM FreeStyleComputer Software Personal Consumer Data CoPilot NA
Software Manager ($79)
Table A-4: Comparison of Cost in Existing CGMS.
MINIMED
PARADIGM" DEXCOM STS FREESTYLE
REAL-TIME CGMS/ SEVEN NAVIGATOR® GLUCODAYS
GUARDIAN* RT
$1,339 for the Receiver and Receiver and
whole system transmitter for transmitter for NA, for clinical
Price ($999 for the $960 to $1040; 6$450, $240 for 4 sensors for $360 use only.CGM only); sensors. sensors for $360
$35/sensor. to $390.
Some people Some people
have obtained have obtained
overage for overage for
sensors sensors
Additional $999 with 10 $250 NA NA
Transmitter sensors
Table A-5: Comparison of FDA Approval and Availability
MINIMED
PARADIGM* DEXCOM STS FREESTYLEFEATURE REAL-TIME CGMS/ SEVEN NAVIGATOR® GLUCODAY-S
GUARDIAN* RT
Europe, India,
Availability Selected Cities in Across U.S. Across U.S. Only in Europe
the U.S.
March, 2008 for Children and March 2006 for
FDA Approval adults >18 years adults >7 years adults >18 years Not Approved
old old old
CE Mark Yes No Yes Yes
6 months on 6 months for
Warranty transistor, 5 years receiver and NA NA
on insulin pump transmitter
Money-Back 30 days return 10 days if
Guarantee policy for package NA NAtransmitter unopened
Closed loop Long term (- Developing
Status sensor and pump year) integration with NA
in clinical trials implantable
sensor
Appendix B - Patent Literature
Table B-1: Patents for the MiniMed Paradigm® REAL-Time Insulin Pump and CGMS
and Guardian" REAL-Time CGMS.
U.S.
S/N PATENT PATENT TITLE ISSUE DATE
NO.
01 6809653 Telemetered characteristic monitor system and method of October 26, 2004
using the same.
External infusion device with remote programming bolus
estimator and/or vibration alarm capabilities. April 22, 2003
03 6554798 External infusion device with remote programming, bolus April 29, 2003
estimator and/or vibration alarm capabilities.
04 6872200 External infusion device with remote programming, bolus March 29, 2005
estimator and/or vibration alarm capabilities.
05 6936029 External infusion device with remote programming, bolus
estimator and/or vibration alarm capabilities. August30,2005
External infusion device with remote programming, bolus06 6979326 December 27, 2005estimator and/or vibration alarm capabilities.
External infusion device with remote programming, bolus
estimator and/or vibration alarm capabilities. February 14,2006
External infusion device with remote programming, bolus
estimator and/or vibration alarm capabilities April 11,2006
Table B-2: Patents for the DexCom SEVEN'" CGMS.
U.S.
S/N PATENT PATENT TITLE ISSUE DATE
NO.
Ii . I I I-. . . / . . . . .• -1 0 6931327 Systems an , 2005
Table B-3: Patents for the Abbott's FreeStyle Navigator".
U.S.
S/N PATENT PATENT TITLE ISSUE DATE
NO
01 5262035 Enzyme electrodes. November 16, 1993
02 5264104 Enzyme electrodes. November 23, 1993
03 5264105 Enzyme electrodes. November 23, 1993
04 5593852 Subcutaneous glucose electrode. January 14, 1997
05 5899855 Modular microprocessor-based health monitoring system. May 4, 1999
06 5918603 Method for treating medical conditions using a July 6, 1999
microprocessor-based video game.
07 5965380 Subcutaneous glucose electrode. October 12, 1999
08 6081391 Enzyme electrode structure. June 6, 2000
09 6103033 Process for producing an electrochemical biosensor. August 15, 2000
10 6120676 Method of using a small volume in vitro analyte sensor. September 19, 2000
11 6021009 Electrochemical analyte measurement system. September 19, 2000
12 6134461 Electrochemical analyte. October 17, 2000
13 6143164 Small volume in vitro analyte sensor. November 07, 2000
14 6162611 Subcutaneous glucose electrode. December 19, 2000
15 6175752 Analyte monitoring device and methods of use. January 16, 2001
16 6284478 Subcutaneous glucose electrode. September 4, 2001
17 6299757 Small volume in vitro analyte sensor with diffusible or non- October 9,2001leachable redox mediator.
18 6329161 Subcutaneous glucose electrode. December 11,2001
19 6338790 Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator. January 15, 2002
20 6461496 Small volume in vitro analyte sensor with diffusible or non- October 8,2002
leachable redox mediator.
21 6486046 Electrochemical analyte sensor. November 19, 2002
22 6503381 Biosensor. January 07, 2003
23 6514718 Subcutaneous glucose electrode. February 4, 2003
24 6560471 Analyte monitoring device and methods of use. Ma6 6, 2003
25 6565509 Analyte monitoring device and methods of use. May 20, 2003
26 6591125 Small volume in vitro analyte sensor with diffusible or non- Jul 8,2003leachable redox mediator. July 8, 2003
27 6592745 Method of using a small volume in vitro analyte sensor with Jul 15,2003diffusible or non-leachable redox mediator. July 15, 2003
28 6605200 Polymeric transition metal complexes and uses thereof. August 12, 2003
29 6605201 Transition metal complexes with bidentate ligand having an August 12,2003imidazole ring and sensor constructed therewith.
30 6616819 Small volume in vitro analyte sensor and methods. September 9, 2003
31 6618934 Method of manufacturing small volume in vitro analyte September 16, 2003
sensor.
32 6676816 Transition metal complexes with (pyridyl)imidazole ligands
and sensors using said complexes January 13, 2004
33 6749740 Small volume in vitro analyte sensor and methods. January 15, 2004
34 6893545 Biosensor. May 17, 2005
35 6932894 Biosensor membranes composed of polymers containing August 23,200569heterocyclic nitrogens. August 23, 2005
36 6942518 Small volume in vitro analyte sensor and methods. September 13, 2005
U.S. PatentS/N Patent Title Issue DateNo
37 6973706 Method of making a transcutaneous electrochemical sensor. December 13, 2005
38 6990366 Analyte monitoring device and methods of use. January 24, 2006
39 7003340 Electrochemical analyte sensor. February 21,2006
40 7003341 Analyte monitoring devices and methods of use. February 21, 2006
41 7074308 Transition metal complexes with (pyridyl)imidazole ligands July 11,2006
and sensors using said complexes. July 11,2006
42 7090756 Image forming method and image forming apparatus. August 15, 2006
t43 7299082 Method of calibrating an analyte-measurement device, and November 20,2007
associated methods, devices and systems.
Table B-4 Patents for SMSI ' CGMS.
U.S.
S/N PATENT PATENT TITLE ISSUE DATE
NO
01 6304766 Optical-based sensing devices, especially for in-situ sensingin humans. October 16,2001
02 6330464 Optical-based sensing devices. December 11,2001
Detection of analytes by fluorescent lanthanide metal
chelate complexes containing substituted ligands.
04 6400974 Implanted sensor processing system and method for June 04, 2002
processing implanted sensor output.
05 6711423 Optical-based sensing devices. March 23, 2004
06 3794195 Detection of analytes in aqueous environments. September 21, 2004
07 6800451 Detection of glucose in solutions also containing an alpha- October 05, 2004hydroxy acid or a beta-diketone.
08 64900974 High performance fluorescent optical sensor. September 06, 2005
09 7016714 Optical-based sensing devices. March 21, 2006
10 7060503 Detection of analytes in aqueous environments. June 13, 2006
11 7078554 Detection of glucose in solution also containing an alpha- July 18, 2006hydroxy acid or a beta-diketone.
12 7135342 Electro-optical sensing device with reference channel. November 14, 2006
13 7157723 System and method for attenuating the effect of ambient January 02, 2007light on an optical sensor.
14 7190445 High performance fluorescent optical sensor. March 13, 2007
15 7227156 System and method for attenuating the effect of ambient June 05, 2007light on an optical sensor.
16 7289836 Optical based sensing devices. October 14, 2006
17 7375347 Systems and methods for extending the useful life of optical May 20, 2008
sensors.
